Bioluminescence imaging is used for longitudinal evaluation of bacteria in live animals. Clear relations exist between bacterial numbers and their bioluminescence. However, bioluminescence images of Staphylococcus aureus Xen29, S. aureus Xen36 and Escherichia coli Xen14 grown on tryptone soy agar in Etests demonstrated increased bioluminescence at sub-MICs of different antibiotics. This study aimed to further evaluate the influence of antibiotic pressure on bioluminescence in S. aureus Xen29. Bioluminescence of S. aureus Xen29, grown planktonically in tryptone soy broth, was quantified in the absence and presence of different concentrations of vancomycin, ciprofloxacin, erythromycin or chloramphenicol and was related to expression of the luxA gene under antibiotic pressure measured using real-time PCR. In the absence of antibiotics, staphylococcal bioluminescence increased over time until a maximum after ca. 6 h of growth, and subsequently decreased to the detection threshold after 24 h of growth owing to reduced bacterial metabolic activity. Up to MICs of the antibiotics, bioluminescence increased according to a similar pattern up to 6 h of growth, but after 24 h bioluminescence was higher than in the absence of antibiotics. Contrary to expectations, bioluminescence per organism (CFU) after different growth periods in the absence and at MICs of different antibiotics decreased with increasing expression of luxA. Summarising, antibiotic pressure impacts the relation between CFU and bioluminescence. Under antibiotic pressure, bioluminescence is not controlled by luxA expression but by co-factors impacting the bacterial metabolic activity. This conclusion is of utmost importance when evaluating antibiotic efficacy in live animals using bioluminescent bacterial strains.
Introduction
Over the past decades, increasing use of biomaterial implants and devices has been accompanied by a concurrent increase in the incidence of biomaterial-associated infections (BAIs). BAIs have now become the main cause of prosthetic implant and device failure [1] , and patients with prosthetic joint infection, for instance, find themselves at a risk of mortality exceeding that of many cancers [2] . Along with the combined search and development of new antibiotic drugs to fight bacterial resistance to antibiotics, new antimicrobial prophylactic and therapeutic measures have been developed to treat bacterial biofilms. Therewith, the need for appropriate methods to evaluate these measures in vitro and in vivo has become of paramount importance, especially in case of BAIs where clinical trials are difficult, requiring large patient groups owing to the relatively low incidence of BAI. Recently, the combination of sensitive bio-optical imaging systems and the availability of bioluminescent bacteria has enabled real-time non-invasive monitoring of the spatiotemporal persistence of bacteria in live animals, and the number of in vitro-and in vivo-based papers relying on bacterial bioluminescence as an indicator of bacterial persistence is rapidly increasing [3] [4] [5] [6] [7] [8] . Clear relations have been found between bioluminescence arising from bacterially contaminated biomaterials in animals and ex vivo bacterial counts after culturing organisms from explanted materials after sacrifice in multiple papers [4, 5, [7] [8] [9] [10] .
Bioluminescent bacteria are genetically engineered by stably integrating the lux operon into their genome or on a plasmid and are equipped with a luciferase reporter system capable of emitting visible light that can be detected by highly sensitive camera systems [6] . The total bioluminescence observed depends on the number of bacteria involved and the bioluminescence per http://dx.doi.org/10.1016/j.ijantimicag.2015.09.007 0924-8579/© 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. individual organism. Bioluminescence per organism is controlled by five essential genes (luxABCDE) [11] as well as different cofactors ( Supplementary Fig. S1 ).
Although several studies have confirmed that bioluminescence relates well to bacterial numbers in a biofilm [3, 4] , it has also been reported that bioluminescence per individual organism changes during the different bacterial growth phases [7, [12] [13] [14] . Furthermore, discrepancies have been pointed out between the number of viable bacteria in a biofilm and their total bioluminescence following exposure to antibiotics [14] . For an illustration of this phenomenon, we present bioluminescence images overlaid on black & white photographs of the agar plates for Staphylococcus aureus Xen29, S. aureus Xen36 and Escherichia coli Xen14 grown on tryptone soy agar (TSA) in Etests against vancomycin, ciprofloxacin, erythromycin and chloramphenicol pressures ( Supplementary Fig.  S2 ).
The aim of this study was to further evaluate the influence of the presence of different antibiotics on staphylococcal bioluminescence and expression of luxA during growth in a commercially available and often used [7, 10, 15] bioluminescent strain, namely S. aureus Xen29.
Materials and methods

Bacterial strain
Staphylococcus aureus Xen29, originating from meticillinsusceptible S. aureus ATCC 12600, was made bioluminescent by inserting a modified Photorhabdus luminescens lux operon (lux-ABCDE) into the bacterial genome [9] , situated within the open reading frame of the hypothetical gene SA2154 [16] . The strain was obtained commercially from PerkinElmer (Waltham, MA).
2.2.
Total bioluminescence of S. aureus Xen29 in planktonic culture in the absence and presence of antibiotic pressure Bacteria were cultured from cryopreservative beads onto TSA (Oxoid Ltd., Basingstoke, UK) in the presence of 200 mg/L kanamycin and were incubated for 24 h at 37 • C in ambient air. Prior to each experiment, one colony was used to inoculate 10 mL of tryptone soy broth (TSB) (Oxoid Ltd.) and was planktonically cultured at 37 • C for 24 h in ambient air. Then, 500 L of each culture was used to inoculate 10 mL of TSB growth medium and was planktonically grown at 37 • C with continuous shaking at 150 rpm for 16 h. Staphylococci were suspended in TSB to a concentration of 5 × 10 6 bacteria/mL as counted in a Bürker-Türk counting chamber.
Next, 200 L aliquots of bacterial suspension in TSB with an antibiotic concentration of 0 (no antibiotic) up to its minimum inhibitory concentration (MIC) were incubated at 37 • C in sterile 96-well plates (Falcon ® ; Corning Inc., Corning, NY). Total bioluminescence was measured over the area of each individual well at 2, 3, 4, 5, 6 and 24 h after inoculation using a highly sensitive, cooled charge-coupled device camera (IVIS ® Lumina Imaging System; PerkinElmer) and was expressed as photons per second (p/s). Note that the total bioluminescence observed is the product of bacterial bioluminescence per individual organism and the number of CFU in the well culture.
Four antibiotics were applied that differ in their mode of antibacterial action: vancomycin is an inhibitor of bacterial cell wall synthesis; ciprofloxacin is an inhibitor of bacterial nucleic acid synthesis; and erythromycin and chloramphenicol prevent bacterial protein synthesis. MICs of S. aureus Xen29 against the different antibiotics were determined using Etest strips (AB BIODISK, Solna, Sweden) on TSA and were read from the photographs presented in Supplementary Fig. S2 : 0.75 mg/L for vancomycin; 0.31 mg/L for ciprofloxacin; 0.25 mg/L for erythromycin; and 2.7 mg/L for chloramphenicol.
Number of viable bacteria
To determine the number of CFU responsible for the total bioluminescence observed, staphylococci were grown for various periods of time in the absence and presence of vancomycin, ciprofloxacin, erythromycin or chloramphenicol at their MIC in 200 mL of TSB. Aliquots of 1 mL were taken from the bacterial suspension at different time points and were serially diluted, after which 100 L of the diluted bacterial suspensions were plated on TSA plates and were incubated at 37 • C. CFU were counted after 24 h of incubation and were expressed as CFU/mL. From the same 200 mL culture, 200 L aliquots were taken and the total bioluminescence (p/s) was measured in a 96-well plate in order to calculate the bioluminescence per CFU while accounting for the different volumes (p/s/CFU).
RNA isolation and luxA expression
Expression of the luxA gene in S. aureus Xen29, harvested from the same bacterial cultures as used for CFU determination, was measured using real-time PCR as described previously [17] after incubation for different times in the absence and presence of vancomycin, ciprofloxacin, erythromycin or chloramphenicol at the different MICs of the antibiotics.
The sequence of S. aureus NCTC 8325-4 was used to design primer sets for gyrB and of P. luminescens for luxA (gyrB f3, 5 -ATATAGGATCGACTTCAGAG-3 ; gyrB r4, 5 -TGAATATCAACTGG-GATACC-3 ; LuxA f1, 5 -GTATTTCTGAGGAGTGTGGT-3 ; LuxA r2, 5 -CTGTTATTCATATCCGTGCC-3 ). Then, 100 nM of each primer was used under a two-step protocol with an annealing temperature of 60 • C. Under the selected conditions, primer efficiency was between 90% and 110% as determined using serial dilutions of chromosomal DNA of S. aureus Xen29.
Total RNA was isolated from aliquots of the growing suspension after different time periods in the absence and presence of the antibiotics up to 24 h at their respective MICs. Bacteria were harvested by centrifugation and were frozen at −80 • C. Samples were thawed slowly on ice and RNA isolation was carried out using a RiboPure TM -Bacteria Kit (Ambion, Foster City, CA). DNA was removed using the Ambion ® DNA-free TM Kit (Applied Biosystems, Foster City, CA) and the absence of genomic DNA was verified by reverse transcription PCR (RT-PCR) prior to reverse transcription. For all samples, 35 cycles of PCR using the gyrB primer set did not result in any detectable signal, confirming the absence of genomic DNA in the RNA preparation. RNA concentrations were determined using an ultraviolet spectrophotometer (NanoDrop, Wilmington, DE), and 250 ng of total RNA was used for cDNA synthesis (iScript TM ; Bio-Rad, Veenendaal, The Netherlands). PCR reactions were prepared in triplicate using a CAS-1200 pipetting robot (Corbett Life Science, Sydney, Australia). Expression levels of luxA in staphylococci were analysed using the 2 − C T method [18] with gyrB as reference and expressed per CFU.
Results
Total staphylococcal bioluminescence after 2, 3, 4, 5, 6 and 24 h of planktonic growth was plotted as a function of antibiotic concentration for each of the antibiotics involved (Fig. 1) . In the absence of antibiotics, staphylococcal bioluminescence increased over time until a maximum occurred after ca. 6 h of growth, and subsequently decreased to the detection threshold after 24 h of growth owing to reduced metabolic activity of the bacteria. Up to the MICs of the Supplementary Fig. S2 ). Data are presented as the median with full ranges indicated by the bars over three independent measurements with separate bacterial cultures.
antibiotics, bioluminescence increased according to a similar pattern up to 6 h of growth, but after 24 h bioluminescence was higher than in the absence of antibiotic. Fig. 2 shows the number of viable S. aureus Xen29 during planktonic growth as a function of time in the absence and presence of antibiotics at their MIC, indicating that bacterial growth is inhibited in presence of antibiotics, whereas after 24 h of growth the number of bacteria approached the number of bacteria grown in the absence of antibiotics.
To determine the bioluminescence per organism during growth, the total bioluminescence observed was divided by the number of CFU and was plotted versus expression of the luxA gene (Fig. 3) . Contrary to expectation, bioluminescence per organism after different growth times in the absence and at the MICs of the different antibiotics decreased significantly with increasing expression of the luxA gene.
Discussion
Bacterial bioluminescence offers a valuable imaging modality to monitor bacterial persistence in in vivo infection models based on frequent observations that bioluminescence is proportional to the number of viable bacteria in a biofilm [4, 5, [7] [8] [9] [10] . The current study, however, shows that the presence of antibiotics not only affects the number of viable bacteria of S. aureus Xen29 but also the bioluminescence per individual organism. Bioluminescence enhancements at sub-MIC antibiotic concentrations were also observed for S. aureus Xen36 and Gram-negative E. coli Xen14 ( Supplementary Fig. S2 ). This attests to the fact that various antibiotics with different modes of antibacterial action have a similar effect on bacterial bioluminescence activity for Gram-positive S. aureus and Gram-negative E. coli. Moreover, bioluminescence per individual organism is not related to luxA gene expression ( Fig. 3) .
Although enhanced bioluminescence activities at sub-MICs have been found before both for E. coli and S. aureus in the presence of trimethoprim [12] and for S. aureus Xen29 at sub-MIC concentrations of vancomycin [10] , the relationship with lux gene expression has never been fully understood. In the literature, there is controversy regarding the origin of variations in bioluminescence activity during growth. Welham and Stekel found on the basis of enzymatic model calculations that bioluminescence is hardly sensitive to cofactors such as NADPH, ATP and oxygen concentration and that the enzymatic luciferase system is mainly sensitive to the availability of aldehydes, which are controlled by luxE and luxD expression [19] . The results presented in Fig. 3 , however, clearly indicate that factors other than expression of lux genes influence the temporal development of bioluminescence. luxA expression in the absence of antibiotics was higher than under antibiotic pressure (see Fig. 3 ), which resembles the known effect of repressed gene transcription by sub-MICs of antibiotics, distinct from their growth inhibitory effects [20] . Also, the negative correlation between bioluminescence and luxA gene expression in the absence and presence of MICs of different antibiotics indicate that factors other than expression of lux genes control the temporal development of bioluminescence.
It has been suggested that the NADPH redox pool, necessary for bacterial respiration to take place, reduces over time in the stationary state in order to limit cell damage due to reactive oxygen products resulting from respiration. Therefore, NADPH, which is crucial for bioluminescence to occur, has been identified [13] as a good candidate to explain the low bioluminescence observed 24 h after incubation (Fig. 1 ) in the absence of antibiotics. It is reasonable to assume that antibiotics have a negative impact on the respiratory processes in the cell, which may, as a defence strategy, lead to an increase of the NADPH pool, therewith enhancing the bioluminescence despite low luxA expression (see Fig. 3 ).
Enhanced bioluminescence under antibiotic pressure may not always be noticed in in vivo experiments because antibiotics may also inhibit bacterial growth, which will compensate and thereby obscure bioluminescence enhancement. In the current study, however, 24 h after inoculation an increasing total bioluminescence was observed with increasing antibiotic concentrations despite the fact that the number of CFU was hardly affected by the presence of antibiotics (compare Figs. 1 and 2) . Accordingly, the observation that different total bioluminescences emanate from equal numbers of bacteria yields the conclusion that total bioluminescence does not always correlate with CFU counts under antibiotic pressure. This is probably due to the changing concentrations of relevant co-factors, such as NADPH, in a bacterium.
In conclusion, antibiotic pressure impacts the relation between CFU and bioluminescence. Under antibiotic pressure up to the MIC, bioluminescence is not controlled by luxA gene expression and the impact of antibiotic pressure on bioluminescence in S. aureus is manifested as a decrease in luxA expression and a likely enhanced availability of co-factors, such as NADPH. As a result, staphylococcal bioluminescence per bacterium may increase under the influence of antibiotics. This implies that the decrease of total bioluminescence from bacteria observed in vivo under antibiotic pressure does not necessarily correlate with eradication of viable bacteria. This effect is not always taken into account in the growing body of literature using bioluminescent bacteria, but must not be neglected when evaluating new antibiotic drugs in vitro or when interpreting in vivo studies in animals using bioluminescence imaging of bacteria in the presence and absence of antibiotics.
